coalition of Italian brains and murderers approach

laura curran in the spirit and memory of phillip msgnsno, fsmily man and us veteran from brooklyn who was treated for trigeminal neuralgia at the us veterans hospital at fort hamilton in brooklyn for trigeminal neuralgia in brooklyn by dr egene j ratner, the lancet p106 jan 14 1978

ratner's social security number is 096-12-1917
The nassau county medical center  whose bonds failure would bankrupt nassau county needs a muscular italian upgrade with italian bcg know how and the replacement of deadwood to plsy cards in the morgue, if pstronage jobs are continued

laura curran should expose morons, infidels, invompetents, and needless mutilators at the medical center and see that the eork f the italian ministry of health is carried forth as endorsed by the great white gurl in boston denise l faustman fsustmanlab.org

Objective: 

To evaluate Bacille Calmette-Guérin (BCG) effects after clinically isolated syndromes (CIS).

Methods: 

In a double-blind, placebo-controlled trial, participants were randomly assigned to receive BCG or placebo and monitored monthly with brain MRI (6 scans). Both groups then entered a preplanned phase with IM interferon-β-1a for 12 months. From month 18 onward, the patients took the disease-modifying therapies (DMTs) that their neurologist considered indicated in an open-label extension phase lasting up to 60 months.

Results: 

Of 82 randomized subjects, 73 completed the study (33 vaccinated and 40 placebo). During the initial 6 months, the number of cumulative lesions was significantly lower in vaccinated people. The relative risks were 0.541 (95% confidence interval [CI] 0.308–0.956; p = 0.03) for gadolinium-enhancing lesions (the primary endpoint), 0.364 (95% CI 0.207–0.639; p = 0.001) for new and enlarging T2-hyperintense lesions, and 0.149 (95% CI 0.046–0.416; p = 0.001) for new T1-hypointense lesions. The number of total T1-hypointense lesions was lower in the BCG group at months 6, 12, and 18: mean changes from baseline were −0.09 ± 0.72 vs 0.75 ± 1.81 (p = 0.01), 0.0 ± 0.83 vs 0.88 ± 2.21 (p = 0.08), and −0.21 ± 1.03 vs 1.00 ± 2.49 (p= 0.02). After 60 months, the cumulative probability of clinically definite multiple sclerosis was lower in the BCG + DMT arm (hazard ratio = 0.52, 95% CI 0.27–0.99; p< 0.05), and more vaccinated people remained DMT-free (odds ratio = 0.20, 95% CI 0.04–0.93; p = 0.04).

Conclusions: 

Early BCG may benefit CIS and affect its long-term course.

Classification of evidence: 

BCG, as compared to placebo, was associated with significantly reduced development of gadolinium-enhancing lesions in people with CIS for a 6-month period before starting immunomodulating therapy (Class I evidence).